Drug Discovery

Trend Analysis: Triple-Agonist Obesity Drugs
Research & Development Trend Analysis: Triple-Agonist Obesity Drugs

The pharmaceutical landscape is currently witnessing a transition where losing twenty percent of body weight is no longer considered the ceiling for success but rather the baseline for entering the competitive arena. For years, the industry relied on single-hormone mimics to manage metabolic

Who's Winning the Latest Drug Development Race?
Research & Development Who's Winning the Latest Drug Development Race?

We are joined by Ivan Kairatov, a biopharma expert with deep insights into the intricate world of drug research and development. In our conversation, we’ll explore the high-stakes landscape of regulatory approvals, touching on Bristol Myers Squibb's pivotal new cancer therapy, the challenging path

Study Finds Muscle Strength Key to a Longer Life
Research & Development Study Finds Muscle Strength Key to a Longer Life

The persistent search for a long and healthy life has often prioritized cardiovascular fitness, yet a groundbreaking study suggests a more fundamental measure of vitality might be found in something as simple as the strength of your grip. This new body of research illuminates a powerful,

Have Scientists Found Leukemia's Off Switch?
Research & Development Have Scientists Found Leukemia's Off Switch?

In the intricate and often relentless world of oncology, a recent discovery has illuminated a previously hidden pathway that governs the very genesis of a deadly blood cancer, suggesting that the key to halting the disease might lie within a mechanism once thought to be part of the problem. This

Review of Axpaxli AMD Treatment
Research & Development Review of Axpaxli AMD Treatment

In the high-stakes world of pharmaceutical development, a successful Phase 3 trial is typically a cause for celebration, yet Ocular Therapeutix's recent announcement for its wet AMD treatment, Axpaxli, was met with a starkly different reality. The drug achieved its primary endpoint with statistical

First Psychedelic Drug for Depression Nears FDA Approval
Research & Development First Psychedelic Drug for Depression Nears FDA Approval

With a major breakthrough in psychedelic medicine, Compass Pathways' psilocybin-based therapy, COMP360, has delivered compelling Phase 3 results, sending shockwaves through the biopharma world and reigniting hope for patients with treatment-resistant depression. To unpack what this means for

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later